Companies /Healthcare

Tilray Brands Inc

NASDAQ: TLRY Drug Manufacturers - Specialty & Generic
$4.50
▼ $0.03 (−0.66%) today
Markets closed · 10:01am ET

Q3 2026 Earnings

Reported Apr 1, 2026, 7:00am ET · SEC source
$0.02
Miss −71.43%
EPS · est. $0.07
$206.7M
Beat +2.70%
Revenue · est. $201.3M
−13.5%
Trailing market
TLRY vs S&P since report
3 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
−10%−5%0Apr 1Apr 2report 7:00am ETearnings−0.2%−2.1%
−10%−5%0Apr 1Apr 2earnings−0.2%−2.1%
TLRY −2.1%S&P 500 −0.2%
−10%−5%0Apr 1Apr 2report 7:00am ETearnings−0.0%−2.1%
−10%−5%0Apr 1Apr 2earnings−0.0%−2.1%
TLRY −2.1%NASDAQ −0.0%
−10%−5%0Mar 31Apr 9report 7:00am ETearnings+2.8%−1.7%
−10%−5%0Mar 31Apr 9earnings+2.8%−1.7%
TLRY −1.7%S&P 500 +2.8%
−12%−6%0Mar 31Apr 9report 7:00am ETearnings+3.5%−1.7%
−12%−6%0Mar 31Apr 9earnings+3.5%−1.7%
TLRY −1.7%NASDAQ +3.5%
−5.10%
Day of report
+6.68%
Next session
+9.45%
One week
−3.91%
30 days

S&P 500 over the same 30 days: +9.58%.

Did TLRY Beat Earnings? Q3 2026 Results

Tilray Brands posted a mixed third fiscal quarter for the period ended February 28, 2026, delivering a revenue beat alongside a meaningful earnings miss that underscored the uneven nature of its recovery. The cannabis and beverage company reported net revenue of $206.73 million, topping the $201.30 million consensus by 2.70%, though the headline figure still represented a 23.0% decline year-over-year. On the bottom line, adjusted EPS of $0.02 fell well short of the $0.07 analyst estimate, a 71.43% miss, as margin compression in the beverage segment weighed on profitability despite international cannabis revenue surging more than 73% to a company record. The distribution segment also contributed record quarterly revenue of $82.96 million, up 35%, helping lift adjusted EBITDA 19% to $10.71 million. With the post-quarter acquisition of BrewDog and a Carlsberg partnership set for 2027, management reaffirmed full-year adjusted EBITDA guidance of $62 million to $72 million, though flagged Middle East geopolitical tensions as a potential headwind to that outlook; a price target cut by at least one analyst reflected lingering skepticism around the path to consistent profitability.

Key Takeaways
  • International cannabis revenue grew 73% year-over-year with 100% increase in cannabis flower sales volume
  • Canadian adult-use and medical cannabis combined revenue increased 8% year-over-year
  • Distribution segment achieved record quarterly net revenue driven by Tilray Pharma
  • Wellness segment revenue grew 16% year-over-year
  • Project 420 synergy program completed, delivering approximately $33 million in annualized cost savings
  • 11% organic revenue growth

“Our third quarter results demonstrated the strength of our global strategy in action, delivering our strongest Q3 net revenue and gross profit to date. Our international cannabis business delivered its best quarterly net revenue in Company history, with over 70% year-over-year growth, which reflects the disciplined execution of our strategy across key global markets. We are seeing that our strategy works, driving growth through scale, product innovation, and strong distribution.”

Tilray Brands CEO, on the earnings call

Forward Guidance & Outlook

Tilray reconfirmed fiscal year 2026 adjusted EBITDA guidance of $62 million to $72 million, representing growth of 13% to 31% compared to fiscal year 2025. The company noted it is monitoring Middle East geopolitical developments, including the escalation of hostilities involving Iran, which may impact energy, fuel, logistics, and supply chain costs and therefore adjusted EBITDA expectations. The BrewDog acquisition (closed after quarter end) and a Carlsberg partnership beginning in 2027 are expected to accelerate the buildout of a global beverage platform across Europe, the Middle East, Australia, Asia-Pacific, and the U.S.

TLRY YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$90.0M$180.0M$270.0M$268.3M$206.7MRevenue$75.1M$55.0MGross Profit$-13,353,239$-26,386,000Operating Income$-12,757,470$-25,233,000Net Income
$0$90.0M$180.0M$270.0MRevenueGross ProfitOperating IncomeNet Income

TLRY Revenue by Segment

Beverage$42.6M
Distribution$83.0M+35.0%
Cannabis$64.8M+19.0%
Canadian Adult-Use Cannabis$52.6M
International Cannabis$24.1M+73.0%
Wellness$16.4M+16.0%
Canadian Medical Cannabis$6.0M
Wholesale Cannabis$1.2M

Figures from SEC filings and company reports. Not investment advice.